Bioptik Technology (4161) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioptik Technology (4161) has a cash flow conversion efficiency ratio of 0.055x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.21 Million ≈ $1.68 Million USD) by net assets (NT$974.69 Million ≈ $30.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bioptik Technology - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Bioptik Technology's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Bioptik Technology total liabilities for a breakdown of total debt and financial obligations.
Bioptik Technology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioptik Technology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Q32 Bio Inc
NASDAQ:QTTB
|
0.229x |
|
Shivalik Rasayan Limited
NSE:SHIVALIK
|
0.010x |
|
Genetec Technology Bhd
KLSE:0104
|
-0.110x |
|
Laurion Mineral Exploration Inc
V:LME
|
-0.278x |
|
Dongwoo Farm To Table Co.Ltd
KQ:088910
|
0.052x |
|
Century Lithium Corp.
V:LCE
|
-0.010x |
|
Major Cineplex Lifestyle Leasehold Property Fund
BK:MJLF
|
0.015x |
|
Marygold Companies Inc
NYSE MKT:MGLD
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Bioptik Technology (2017–2025)
The table below shows the annual cash flow conversion efficiency of Bioptik Technology from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Bioptik Technology worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$974.69 Million ≈ $30.71 Million |
NT$59.99 Million ≈ $1.89 Million |
0.062x | -64.92% |
| 2024-12-31 | NT$905.27 Million ≈ $28.52 Million |
NT$158.82 Million ≈ $5.00 Million |
0.175x | -29.79% |
| 2023-12-31 | NT$824.15 Million ≈ $25.97 Million |
NT$205.95 Million ≈ $6.49 Million |
0.250x | +225.81% |
| 2022-12-31 | NT$717.83 Million ≈ $22.62 Million |
NT$55.06 Million ≈ $1.73 Million |
0.077x | +229.45% |
| 2021-12-31 | NT$694.54 Million ≈ $21.88 Million |
NT$-41.15 Million ≈ $-1.30 Million |
-0.059x | -763.13% |
| 2020-12-31 | NT$735.66 Million ≈ $23.18 Million |
NT$6.57 Million ≈ $207.09K |
0.009x | -83.27% |
| 2019-12-31 | NT$768.38 Million ≈ $24.21 Million |
NT$41.03 Million ≈ $1.29 Million |
0.053x | +3.64% |
| 2018-12-31 | NT$811.73 Million ≈ $25.57 Million |
NT$41.83 Million ≈ $1.32 Million |
0.052x | +314.97% |
| 2017-12-31 | NT$887.42 Million ≈ $27.96 Million |
NT$11.02 Million ≈ $347.16K |
0.012x | -- |
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. It offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch Glucose Monitoring System for Dogs and Cats. The company also prov… Read more